Back to results
US 5,631,224 AGranted
Use of a peptide
AssigneeNovo Nordisk A/S
InventorsSuad Efendic, Mark Gutniak, Ole Kirk
Life of this patent
Estimating the term…
Abstract
The invention employs GLP-1(7-37), GLP-1(7-36)amide, and certain related compounds in combination with an oral hypoglycaemic agent for treating diabetes mellitus.
Claims12
A method of treating diabetes which method comprises administering an effective amount of GLP-1(7-36)amide, GLP-1(7-37), or a fragment thereof which retains GLP-1(7-37)activity, to a patient in need of such a treatment in a regimen which additionally comprises treatment with an oral hypoglycaemic agent, wherein said hypoglycaemic agent is characterized as acting on an ATP-dependent potassium channel.
Dependencies are inferred from the claim text.